恶性肿瘤患者血清肌酸激酶同工酶高于肌酸激酶原因分析  

The analysis of malignant tumor patients' serum CK- MB higher than CK

作　　者：王洋[1] 田佳勋[1] 余宪[1] 于洪[1] 

机构地区：[1]辽宁省肿瘤医院检验科,辽宁沈阳110042

出　　处：《现代肿瘤医学》2015年第5期676-677,共2页Journal of Modern Oncology

基　　金：辽宁省自然基金资助项目(编号:201202118)

摘　　要：目的:探讨恶性肿瘤患者血清肌酸激酶同工酶(CK-MB)活性高于肌酸激酶(CK)的原因。方法:在VITROS5600全自动生化免疫分析仪上测定恶性肿瘤患者血清CK-MB和CK活性。结果:5612例恶性肿瘤患者血清中139例CK-MB活性高于CK活性,占恶性肿瘤患者的2.5%。恶性肿瘤患者中,O型与B型血占65%。结论:CK-MB活性高于CK活性除了方法学所致原因之外,恶性肿瘤患者免疫力低下或病情加重也是重要的影响因素。Objective：To explore the reason of malignant tumor patientsˊ serum CK - MB higher than CK. Meth-ods：Use VITROS5600 automatic biochemical analyzer to determine malignant patients serum CK - MB and CK activi-ty. Results：In 139 cases of 5612 malignant tumors patients,CK - MB activity is higher than that of CK activity,ac-counting for 2. 5% . Among these malignant tumor patients,O - and B - type blood accounted for 65% . Conclusion：Other than methodology reasons,immune system disorder and sicker patients are also factors that lead to CK - MB ac-tivity higher than CK.

关 键 词：恶性肿瘤患者 肌酸激酶同工酶 肌酸激酶 

分 类 号：R730.5[医药卫生—肿瘤]